Abstract. Fetal growth restriction (FGR) is a gynecological disorder of varying etiology. In the present study, an expression analysis of pregnancy-associated plasma protein A (PAPPA), pregnancy-associated plasma protein A2 (PAPPA2) and placenta-specific-1 (PLAC-1) was conducted in pregnancies with FGR and control pregnancies. Placental tissues were collected from pregnancies with FGR (n=16) and control pregnancies (n=16) and the expression of the genes of interest was examined by qPCR. The mean expression levels of PAPPA and PAPPA2 were significantly lower (P<0.001) in placental tissues from FGR pregnancies compared with tissues from healthy subjects, whereas the opposite pattern was observed for PLAC-1 (P<0.001). PAPPA and PLAC-1 expression in FGR and control subjects correlated with birth weight (P<0.001). The findings suggest a possible pathophysiological link between the development of FGR and the expression of PAPPA, PAPPA2 and PLAC-1.

Introduction

Fetal growth restriction (FGR) is a complex disorder of pregnancy with varying etiology. It is characterized by the failure of the fetus to achieve its normal growth potential and is associated with perinatal morbidity and mortality, as well as cardiovascular disease in adult life (1). A number of different causes have been attributed to the development of FGR including infections, drug abuse, as well as immunological and anatomical factors. Notably, placental dysfunction is one of the predominant causes of FGR. Despite extensive research into the mechanism underlying the development of FGR, its exact etiology remains elusive. Several hormones that are involved in pregnancy have been investigated with regard to FGR (2). The disease is thought to result from an abnormal placenta and thus identification of the genes involved in abnormal placenta development may enlighten our existing knowledge regarding the pathogenesis of FGR.

Pregnancy-associated plasma protein A (PAPPA) is a syncytiotrophoblast-derived metalloproteinase that cleaves the complex formed between insulin-like growth factor (IGF) and insulin like growth factor binding protein (IGFBP). Serum levels of PAPPA have been examined in relation to various pathological disorders such as stillbirth, infant death, preterm birth, and pre-eclampsia, as well as certain chromosomal disorders and anomalies (3). It is generally accepted that plasma levels of PAPPA are decreased in intrauterine growth restriction (IUGR). Pregnancy-associated plasma protein A2 (PAPPA2) is a protein that shares approximately 40% amino acid homology with PAPPA and functions in a similar manner as an IGFBP protease. The physiological importance of PAPPA2 is not known. However, it is thought that PAPPA2 deficiency plays a major role in growth retardation as documented by studies in k/o mice (4). A 25-30% lower body weight and smaller organs were observed for the PAPPA2 k/o strain (4). In addition to PAPPA proteins, placenta-specific-1 (PLAC-1) is a protein that has been examined as a biomarker for genetic and gestational disorders, since its expression is restricted to cells of the trophoblastic lineage and is absent from adult or fetal tissues. PLAC-1 ablation is associated with placentomegaly and IUGR (7). The exact function of this protein remains unknown and PLAC-1 expression has been
further demonstrated in a variety of human cancers, and is likely to have a significant role in modulating proliferation, invasion and survival of cancer cells (6-8).

Although abnormally low PAPPA and PAPPA2 levels in the first trimester maternal circulation are associated with increased risk of the disease, the expression of the aforementioned markers differs as regards the localization of the proteins in the placenta and/or in the plasma of pregnant women. The aim of the present study was to examine the placental expression levels of PAPPA, PAPPA2 and PLAC-1 in pregnancies with FGR and healthy pregnancies. Our investigation was further focused on the putative associations of the placental expression of the aforementioned biomarkers with the occurrence of FGR.

Materials and methods

**Study group.** The study comprised 16 cases of women with FGR and 16 normotensive subjects undergoing healthy pregnancy. Gestational age (GA) was defined by the last menstrual period. GA was corrected at 11-13 weeks of pregnancy in the cases where the gestational dates were uncertain. Medical history and pregnancy characteristics were recorded from maternity computerized records. An ultrasound examination for biometry of the fetus and Doppler studies were conducted in the third trimester of pregnancy. All the protocols were carried out according to the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guidelines (9).

During delivery of the fetus samples from the placenta, samples were collected from both FGR and control (CT) groups. The tissue size ranged from 4 to 6 mm³ and tissue specimens were snap frozen in liquid N₂ and further stored at -80°C until processing. The study protocol was approved by the Ethics Committee of the National Kapodistrian University of Athens (Athens, Greece) and written informed consent was obtained from all the participants.

**Selection criteria.** FGR was defined according to the International Society for the study of Hypertension in Pregnancy (10). Specifically, women after 20 weeks of gestation who presented with a fetus with reduced growth velocity (<10th percentile) were classified as FGR subjects. Women with pre-existing diabetes type I and II, pre-existing hypertension and gestational diabetes mellitus were excluded from the selection criteria. The CT group included women undergoing pregnancies with a normal third trimester ultrasound scan.

**RNA extraction and reverse transcription.** RNA was extracted with TRIzol as described previously (11). Briefly each tissue was cut to small sections and homogenized with 1 ml TRIzol. The resulting mixture was vortexed with 200 µl chloroform and centrifuged for 15 min at 18,900 g. RNA was extracted from the top layer containing the organic phase and mixed with an equal volume of cold isopropanol. The samples were centrifuged for 10 min at 11,200 g and the resulting RNA pellet was washed once with 70% ethanol and resuspended in 40 µl of diethyl pyrocarbonate-treated water. cDNA was synthesized using a Takara cDNA synthesis kit (Takara Bio, Inc., Otsu, Japan) following the manufacturer's protocol. The RNA was incubated with a reaction mixture containing reaction buffer, RNase inhibitor, reverse transcriptase and water at 43°C for 1 h.

**Quantitative polymerease chain reaction (qPCR).** qPCR was conducted using SYBR at a final reaction volume of 20 µl in a Mx3000 Stratagene PCR amplifier (Agilent Technologies, Inc., Santa Clara, CA, USA). The primers were used at a final concentration of 0.5 µM. The sequences used for amplification of PAPPA, PAPPA2 and PLAC-1 were as follows: PAPPA, forward: GTCATCTTTCCTGGAAGGGGAGAA at 56°C (12) and reverse: AGGGCTGTTCATACAGGATGAC, PAPPA2, forward: ACTCACCCAAGAGGGCATACATGA at 50°C (12) and reverse: GCACGCTGCTGGCAAAGTAGATGTG, PLAC-1, forward: ATTTGGCTGCAAGGAGATGAAAG at 50°C (13) and reverse: TGCACTCTGACCATGACCA.

The quantification was conducted using a standard curve for each primer set. A pool cDNA was prepared that was diluted at: 1:5, 1:25, 1:125 and 1:625. The GAPDH and TOP1 genes were used as housekeeping genes, according to previously published studies (14). The expression levels were presented as normalized values of expression of each gene.

**Statistical analysis.** Significant differences were determined for the demographic parameters using the Mann-Whitney U test, while statistical comparison of the mean levels of expression of the PAPPA, PAPPA2 and PLAC-1 genes was conducted using independent variables t-test. Correlation analysis was conducted using the Pearson's correlation test. A P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Placental levels of PAPPA, PAPPA2 and PLAC-1.** The demographic parameters of the study are shown in Table I. The sample size consisted of 16 pregnant women with FGR and 16 normal pregnancies. The parameters age, height and weight of pregnant women were not significantly different between the control and FGR pregnancies. Significant differences were obtained for GA (P=0.024) and infant weight (P<0.001) with the FGR group exhibiting lower mean values of the two parameters compared to the CT group. This result was expected given the presentation of the disease, which manifested with lower growth characteristics of fetuses compared to normal pregnancies. In addition to the demographic characteristics, the placental mRNA expression levels of PAPPA, PAPPA2 and PLAC-1 were determined by qPCR. The mean expression levels of PAPPA and PAPPA2 were lower in the IUGR group compared to those of the CT group (Fig. 1). The differences were statistically significant as demonstrated by the corresponding P-values (P<0.001) (Table II). In contrast to these observations, PLAC-1 exhibited higher values in the FGR pregnancies compared to those of normal pregnancies (Fig. 1 and Table II), thus presenting an opposite pattern of expression between the two groups compared to PAPPA and PAPPA2. This difference was highly significant as determined by the independent sample t-test (P<0.001).

**Linear regression analysis.** Furthermore, correlation analyses revealed positive correlations of PLAC-1 (P<0.05) and PAPPA
expression levels with birth weight, while with regard to PAPPA2 the results were not statistically significant (Fig. 2 and Table III). No significant correlation was noted with regard to the expression levels of these genes with the birth weight of the FGR subjects (Table III). However, the correlation of the birth weight of the FGR subjects with the birth weight of the FGR patients (n=16) and control pregnancies (n=16). Statistical differences were determined using independent samples t-test and the level of significance was set at 0.05. PAPPA, pregnancy-associated plasma protein A; PAPPA2, pregnancy-associated plasma protein A2; PLAC-1, placenta-specific-1; FGR, fetal growth restriction; SD, standard deviation.

Figure 1. The placental expression levels of the markers PAPPA, PAPPA2 and PLAC-1 in FGR and control pregnancies. The expression levels were evaluated by qPCR analysis and normalized against the housekeeping genes GAPDH and TOP1. The results are expressed as mean ± SD for FGR patients (n=16) and control pregnancies (n=16). Statistical differences were determined using independent samples t-test and the level of significance was set at 0.05. PAPPA, pregnancy-associated plasma protein A; PAPPA2, pregnancy-associated plasma protein A2; PLAC-1, placenta-specific-1; FGR, fetal growth restriction; SD, standard deviation.

(P<0.01) expression levels with birth weight, while with regard to PAPPA2 the results were not statistically significant (Fig. 2 and Table III). No significant correlation was noted with regard to the expression levels of these genes with the birth weight of the FGR subjects (Table III). However, the correlation of the birth weight of the FGR subjects with the
expression levels of PAPPA2 was stronger compared with that noted in the total population (-0.3358 vs. 0.21, Table III).

**Discussion**

The present study demonstrated an expression analysis of PAPPA, PAPPA2 and PLAC-1 in pregnancies with FGR and control pregnancies. The mean expression levels of PAPPA and PAPPA2 in placental tissues were significantly lower in FGR pregnancies compared with healthy subjects, whereas the opposite pattern was observed for PLAC-1. The data further demonstrated a correlation of PAPPA and PLAC-1 expression in FGR and control subjects with birth weight, suggesting a possible link of these biomarkers with FGR pathology.

---

**Table II. Statistical analysis of average and range parameters of the expression levels of PAPPA, PAPPA2 and PLAC-1 genes in the FGR and control groups.**

| Expression levels | Groups | No. | Mean   | SD   | Median | Min | Max | P-value |
|-------------------|--------|-----|--------|------|--------|-----|-----|---------|
|                   | Control | 16  | 9.4    | 5.9  | 9.1    | 2.1 | 23.0| <0.001  |
| PAPPA             | FGR     | 16  | 2.8    | 1.4  | 2.6    | 1.1 | 5.9 |         |
|                   | Total   | 32  | 6.1    | 5.4  | 3.9    | 1.1 | 23.0|         |
| PAPPA2            | Control | 16  | 8.8    | 5.5  | 6.7    | 2.3 | 23.1| <0.001  |
|                   | FGR     | 16  | 5.7    | 2.7  | 5.5    | 2.1 | 10.3|         |
|                   | Total   | 32  | 7.2    | 4.5  | 5.9    | 2.1 | 23.1|         |
| PLAC-1            | Control | 16  | 8.1    | 3.2  | 8.1    | 2.5 | 15.5| <0.001  |
|                   | FGR     | 16  | 42.9   | 21.6 | 39.5   | 21.0| 91.8|         |
|                   | Total   | 32  | 25.5   | 23.3 | 18.3   | 2.5 | 91.8|         |

PAPPA, pregnancy-associated plasma protein A; PAPPA2, pregnancy-associated plasma protein A2; PLAC-1, placenta-specific-1; FGR, fetal growth restriction; SD, standard deviation.

---

**Figure 2. Correlation analysis of PAPPA, PAPPA2 and PLAC-1 expression with birth weight in FGR and control pregnancies.** The results are expressed as correlation scatter plots for FGR patients (n=16) and control pregnancies (n=16) in each plot. The significant differences and the Pearson’s coefficient r were determined using Pearson’s correlation analysis and the level of significance was set at 0.05. PAPPA, pregnancy-associated plasma protein A; PAPPA2, pregnancy-associated plasma protein A2; PLAC-1, placenta-specific-1; FGR, fetal growth restriction.
Table III. Correlation analysis of PAPPA, PAPPA2 and PLAC1 expression with birth weight in FGR pregnancies.

| Genes | P-value | r    | Significance | 95% CI     |
|-------|---------|------|--------------|------------|
| PAPPA | 0.2     | 0.35 | No           | -0.21-0.73 |
| PAPPA2| 0.2     | -0.34| No           | -0.73-0.21 |
| PLAC-1| 0.8     | 0.06 | No           | 0.47-0.55  |

The significant differences and the Pearson's coefficient r were determined using Pearson's correlation analysis and the level of significance was set at 0.05. PAPPA, pregnancy-associated plasma protein A; PAPPA2, pregnancy-associated plasma protein A2; PLAC-1, placenta-specific-1; FGR, fetal growth restriction; SD, standard deviation; CI, confidence intervals.

Previous studies have shown that PAPPA is a biomarker that is decreased in the serum of women who present with FGR in the first trimester (15,16). Giudice et al have demonstrated that neonatal weights are associated with serum PAPPA levels lower than the 25th centile (17). The exact mechanism that contributes to this outcome remains unclear, although PAPPA deficiency has been shown to result in compromised fetal growth and skeletal phenotypes in k/o mice (4). However, it is believed that serum PAPPA levels cannot be used as a reliable biomarker for FGR pathology, since similar biochemical measurements have been noted for preterm delivery, stillbirth and preeclampsia (18,19). Since PAPPA and PAPPA2 are expressed at high levels in the placenta we hypothesized that an altered expression of these biomarkers may influence the development of FGR. Although serum levels of PAPPA rise and fall during the periods of FGR pregnancy we found that placental levels of PAPPA and PAPPA2 were significantly lower in FGR compared with control pregnancies, whereas PAPPA expression correlated with birth weight. This finding is in agreement with the study of Kodama et al where decreased mean levels of placental PAPPA mRNA were reported in late onset preeclampsia compared with healthy pregnancy (13). The possible explanation for these observations is attributed to the levels of the substrate IGFBP-5 that are inversely related to PAPPA2 levels and regulate cytotrophoblast invasion, a key step in placenta development (20). With regard to PAPPA the degradation of the similar protein IGFBP4 leads to the release of IGF-II, which promotes placental development via trophoblast invasion (21). Whether altered expression of these biomarkers is the cause or the effect of FGR remains to be determined.

The present study is in agreement with the report of Kodama et al, with the exception of the difference in the pathological state of the subjects examined (FGR vs. pre-eclampsia) (13). In addition, a previous study indicated lower PAPPA multiples of median levels in SGA (small for GA) cases compared with control subjects (21). The same effect was noted for PAPPA2 following stratification according to maternal hypertension and proteinuria (21). It is believed that the changes in the expression levels of PAPPA2 and PAPPA are associated with the expression of the substrates IGFBP-5 and IGFBP4 that regulate cytotrophoblast invasion, a key step in placenta development (19,22).

In addition to the PAPPA biomarkers, the expression analysis of the novel X-linked gene PLAC-1 in FGR and normal pregnancies revealed marked differences between the two groups. Disruption of PLAC-1 can cause hyperplasia and FGR, whereas PLAC-1 is also reported to be one of the upregulated genes in the hyperplastic placenta generated by nuclear transfer (23). Although the association of PLAC-1 with the development of FGR during pregnancy has not been examined to date, previous studies demonstrated elevated levels of circulating PLAC-1 mRNA in preeclampsia that were directly related to the disease severity (24-26). In a similar manner, increased levels of PLAC-1 in the placenta of FGR-women were observed in the present study, possibly suggesting a feedback mechanism, in order to overcome the development of the disease. Consistent with this hypothesis is the observation that PLAC-1 participates in the maintenance of pregnancy via the adaptation of the placenta to various physiological and environmental stimuli (27). A key feature of the function of PLAC-1 is the modulation of signaling pathways that regulate the cell membrane response to the extracellular environment, with respect to cell shape, motility and plasticity (27).

In conclusion, the present study demonstrated the selective overexpression of placental PLAC-1 and the reduced expression of PAPPA and PAPPA2 in pregnancies associated with FGR compared with healthy pregnancies. Future studies with higher number of samples should focus on the clinical value of PLAC-1 as a predictive biomarker for FGR, by addressing the expression of the latter protein in the serum of women throughout the stages of pregnancy.

Acknowledgements

We would like to thank the department of Toxicology at the Medical School of the University of Crete for allowing us to use the Mx3000 Stratagene PCR amplifier.

Funding

Funding was received by the Medical School of the University of Crete.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

VPA made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data and was involved in drafting the manuscript or revising it critically for important intellectual content. AP, AV and GIP were involved in drafting the manuscript or revising it critically for important intellectual content. SS and NS made substantial contributions to the acquisition of data and gave final approval of the version to be published. DAS gave final approval of the version to be published.
Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of the National Kapodistrian University of Athens (Athens, Greece) and written informed consent was obtained from all participants.

Consent for publication

Written informed consent was obtained from all human subjects regarding their participation in the study.

Competing interests

D.A. Spandidos is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article.

References

1. Gourvas V, Dalpa E, Konstantinidou A, Vrachnis N, Spandidos DA and Sifakis S: Angiogenic factors in placentas from pregnancies complicated by fetal growth restriction (Review). Mol Med Rep 6: 23-27, 2012.
2. Hashimoto Y, Kawai M, Nagai S, Matsukura T, Niwa F, Hasegawa T and Heike T: Fetal growth restriction but not preterm birth is a risk factor for severe hypospadias. Peditr Int 58: 573-577, 2016.
3. Patil M, Panchanadikar TM and Wagh G: Variation of papp-a level in the first trimester of pregnancy and its clinical outcome. J Obstet Gynaecol India 64: 116-119, 2014.
4. Conover CA, Boldt HB, Bale LK, Clifton KB, Grell JA, Mader JR, Mason EJ and Powell DR: Pregnancy-associated plasma protein-A2 (PAPPA2): Tissue expression and biological consequences of gene knockout in mice. Endocrinology 152: 2837-2844, 2011.
5. Kong X, Jackman SM and Fant ME: Plac1 (placenta-specific 1) is widely expressed during fetal development and is associated with a lethal form of hydrocephalus. Birth Defects Res A Clin Mol Teratol 97: 571-577, 2013.
6. Devor EJ, Gonzalez-Bosquet J, Warrier A, Reyes HD, Ikib NV, Schickling BM, Newton A, Goodheart MJ and Leslie KK: p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. Int J Oncol 50: 1721-1728, 2017.
7. Wu Y, Lin D, Xi Y, Chen Y, Zhao H and Wang X: Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells. Oncol Rep 37: 465-473, 2017.
8. Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C and Türeci O: A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes, Cancer Res 67: 9528-9534, 2007.
9. ACOG Committee on Practice Bulletins-Obstetrics: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99: 159-167, 2002.
10. Kappou D, Sifakis S, Androustopoulos V, Konstantinidou A, Spandidos DA and Papantoniou N: Placental mRNA expression of angiopoietins (Ang)-1, Ang-2 and their receptor Tie-2 is altered in pregnancies complicated by preeclampsia. Placenta 35: 718-723, 2014.
11. Androustopoulos VP and Tsatsakis AM: Benzo[a]pyrene sensitizes MCF7 breast cancer cells to induction of GI arrest by the natural flavonoid eupatorin-5-methyl ether, via activation of cell signaling proteins and CYP1-mediated metabolism. Toxicol Lett 230: 304-313, 2014.
12. Wagner PK, Otomo A and Christians JK: Regulation of pregnancy-associated plasma protein A2 (PAPPA2) in a human placental trophoblast cell line (BeWo). Reprod Biol Endocrinol 9: 48, 2011.
13. Kodama M, Miyoshi H, Fujito N, Samura O and Kudo Y: Plasma mRNA concentrations of placenta-specific 1 (PLAC1) and pregnancy associated plasma protein A (PAPP-A) are higher in early-onset than late-onset pre-eclampsia. J Obstet Gynaecol Res 37: 313-318, 2011.
14. Kaitu'u-Lino TJ, Hastie R, Cannon P, Lee S, Stock O, Hannan NJ, Hiscock R and Tong S: Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. Placenta 35: 1106-1109, 2014.
15. Gentile M, Schifano M, Lunardi S, Nanini C, Moscuzza F, Sergiampietri C, Cioutelli M, Monacci F, Boldrini A and Luchi C: Maternal PAPP-A levels at 11-13 weeks of gestation predict foetal and neonatal growth. Open J Obstet Gynecol 5: 365-372, 2015.
16. Gaccioli F, Lager S, Sovio U, Charnock-Jones S and Smith GCS: The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes. Placenta 59: S17-S25, 2017.
17. Giudice I, Benintende G, Di Nicolò AM, Mangiameli D, Carrara G, Randuzzo C, Sapuppo IM and Gulisano A: Correlation of neonatal weight with maternal serum levels of pregnancy-associated plasma protein-A during the first trimester of pregnancy: A retrospective study. J Perinat Med 43: 227-232, 2015.
18. Park HJ, Shim SS and Cha DH: Combined screening for early detection of pre-eclampsia. Int J Mol Sci 16: 17952-17974, 2015.
19. Zhong Y, Zhu F and Ding Y: Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: Systematic review and meta-analysis. BMC Pregnancy Childbirth 15: 191, 2015.
20. Wagner PK and Christians JK: Altered placental expression of PAPPA2 does not affect birth weight in mice. Reprod Biol Endocrinol 8: 90, 2010.
21. Wang J, Qiu Q, Haider M, Bell M, Gruslin A and Christians JK: Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. J Endocrinol 202: 337-345, 2009.
22. Kramer AW, Lamale-Smith LM and Winn VD: Differential expression of human placental PAPP-A2 over gestation and in preeclampsia. Placenta 37: 19-25, 2016.
23. Muto M, Fujihara Y, Tobita T, Kiyozumi D and Ikawa M: Lentiviral vector-mediated complementation restored fetal viability but not placental hyperplasia in Plac1-deficient mice. Hum Mol Genet 25: 4687-4698, 2016.
24. Fant M, Farina A, Nagaraja R and Schlessinger D: PLAC1 (Placenta-specific 1): A novel, X-linked gene with roles in reproductive and cancer biology. Prenat Diagn 30: 497-502, 2010.
25. Purwosunu Y, Sekizawa A, Farina A, Wibowo N, Okazaki S, Nakamura M, Samura O, Fujito N and Okai T: Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat Diagn 27: 772-777, 2007.
26. Zanello M, Sekizawa A, Purwosunu Y, Curti A and Farina A: Circulating mRNA for the PLAC1 gene as a second trimester marker (14-18 weeks' gestation) in the screening for late preeclampsia. Fetal Diagn Ther 36: 196-201, 2014.
27. Fant ME, Fuentes J, Kong X and Jackman S: The nexus of pre maturity, birth defects, and intrauterine growth restriction: A role for placi-regulated pathways. Front Pediatr 2: 8, 2014.